| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
N/A |
| Shares
Out: |
61,150,000 |
| Market
Cap: |
6.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$113.49 - $145.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
12,000 |
12,000 |
12,000 |
| Total Buy Value |
$0 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
5,000 |
8,704 |
24,601 |
181,935 |
| Total Sell Value |
$548,250 |
$986,699 |
$3,178,219 |
$26,303,629 |
| Total People Sold |
1 |
2 |
12 |
19 |
| Total Sell Transactions |
1 |
3 |
19 |
67 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Smith Karen L. |
Global Head of R&D and CMO |
• – – |
2016-08-12 |
4 |
AB |
$137.10 |
$83,356 |
D/D |
608 |
14,182 |
|
- |
|
| Winningham Rick E |
Director |
– • – |
2016-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
16,024 |
|
- |
|
| Sohn Catherine A. |
Director |
– • – |
2016-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
6,749 |
|
- |
|
| Schnee Elmar |
Director |
– • – |
2016-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
5,175 |
|
- |
|
| Riedel Norbert G |
Director |
– • – |
2016-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
5,586 |
|
- |
|
| Okeefe Kenneth W |
Director |
– • – |
2016-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
12,107 |
|
- |
|
| Mulligan Seamus |
Director |
– • – |
2016-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
1,075,976 |
|
- |
|
| Mcsharry Heather Ann |
Director |
– • – |
2016-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
6,761 |
|
- |
|
| Gray Peter |
Director |
– • – |
2016-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
6,754 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2016-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
2,675 |
|
- |
|
| Berns Paul L |
Director |
– • – |
2016-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
5,867 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2016-08-09 |
4 |
D |
$150.01 |
$1,360,741 |
D/D |
(9,071) |
290,113 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2016-08-09 |
4 |
AS |
$150.00 |
$150,000 |
D/D |
(1,000) |
299,184 |
|
- |
|
| Mcgill Iain |
SVP, Europe & Rest of World |
• – – |
2016-08-09 |
4 |
D |
$150.01 |
$409,377 |
D/D |
(2,729) |
18,422 |
|
- |
|
| Hooper Suzanne Sawochka |
EVP & General Counsel |
• – – |
2016-08-09 |
4 |
D |
$150.01 |
$684,796 |
D/D |
(4,565) |
36,699 |
|
- |
|
| Wilson Karen J |
SVP, Finance & PAO |
• – – |
2016-08-09 |
4 |
D |
$150.01 |
$220,065 |
D/D |
(1,467) |
16,710 |
|
- |
|
| Cox Russell J. |
EVP & COO |
• – – |
2016-08-09 |
4 |
AS |
$148.66 |
$594,640 |
D/D |
(4,000) |
51,038 |
|
- |
|
| Cox Russell J. |
EVP & COO |
• – – |
2016-08-09 |
4 |
D |
$150.01 |
$684,796 |
D/D |
(4,565) |
55,038 |
|
- |
|
| Cox Russell J. |
EVP & COO |
• – – |
2016-08-07 |
4 |
D |
$149.02 |
$145,742 |
D/D |
(978) |
59,603 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2016-07-15 |
4 |
AS |
$142.43 |
$14,243 |
D/D |
(100) |
17,625 |
|
- |
|
| Smith Karen L. |
Global Head of R&D and CMO |
• – – |
2016-07-13 |
4 |
AB |
$143.63 |
$83,305 |
D/D |
580 |
13,574 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2016-06-15 |
4 |
AS |
$149.64 |
$14,964 |
D/D |
(100) |
17,725 |
|
- |
|
| Smith Karen L. |
Global Head of R&D and CMO |
• – – |
2016-06-13 |
4 |
AB |
$149.61 |
$83,335 |
D/D |
557 |
12,994 |
|
- |
|
| Mulligan Seamus |
Director |
– • – |
2016-05-24 |
4 |
AS |
$148.65 |
$4,203,339 |
D/D |
(27,968) |
1,074,611 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2016-05-16 |
4 |
AS |
$145.20 |
$14,520 |
D/D |
(100) |
17,753 |
|
- |
|
881 Records found
|
|
Page 25 of 36 |
|
|
0.37 (0.34%) 
